Latest news with #CPTX2309
Yahoo
09-07-2025
- Business
- Yahoo
Morgan Stanley Maintained an Overweight Rating on AbbVie (ABBV)
AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and a $250 price target on AbbVie, in light of the company's recent acquisition announcement. Recently, AbbVie announced its intention to acquire Capstan Therapeutics, a clinical-stage biotechnology firm specializing in in-vivo cell engineering through RNA delivery platforms, for up to $2.1 billion in cash, contingent upon standard closing conditions. The company has a robust financial foundation, including a 71% gross profit margin and 5.45% year-over-year revenue growth, making AbbVie strategically positioned to integrate this acquisition and advance its innovation pipeline. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. As part of the agreement, AbbVie Inc. (NYSE:ABBV) will gain access to CPTX2309, an in-vivo anti-CD19 CAR-T candidate currently undergoing Phase 1 clinical evaluation for B cell-mediated autoimmune disorders. The acquisition also includes Capstan's proprietary lipid nanoparticle (LNP) platform, which enables targeted RNA delivery for the in-vivo engineering of specific cell populations. According to Morgan Stanley, the deal represents a constructive step forward for AbbVie, enhancing its technological capabilities and reinforcing its pipeline in early-stage immunological research. This move complements AbbVie's previously outlined growth agenda, which forecasts expansion through 2032, with recent technology acquisitions offering critical optionality and pipeline diversification. AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company focused on the discovery, development, and commercialization of therapies including immunology, oncology, neuroscience, virology, and ophthalmology. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
05-07-2025
- Business
- Business Insider
AbbVie's (ABBV) Forecasts Lower Q2 EPS on R&D Costs
AbbVie (ABBV) expects a $0.42 drop in second-quarter earnings per share (EPS), driven by a hefty $823 million pre-tax expense tied to acquired research and development (R&D) and milestone payments. The pharmaceutical giant is doubling down on external innovation to expand its drug pipeline. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. These expenses stem from deals like collaborations and licensing agreements, but AbbVie does not forecast them in advance due to their unpredictable timing. As a result, AbbVie has revised its Q2 adjusted EPS guidance to $2.84–$2.88, down from earlier projections. Full-year guidance has also been trimmed to $11.67–$11.87, reflecting the impact of the one-time charge. AbbVie Eyes Long-Term Growth The expense reflects AbbVie's strategy to secure future growth amid looming patent expirations, especially for its key immunology drug, Humira. By investing in new drug candidates and technologies, the company aims to maintain its competitive edge in key therapeutic areas like oncology, neuroscience, and immunology. While investors may be rattled by the earnings dip, the move signals a long-term play. AbbVie's pipeline includes over 90 programs in clinical development, with more than half in mid- or late-stage trials. ABBV Makes $2.1B Bet on Capstan The guidance cut follows the company's announcement of a $2.1 billion Capstan Therapeutics acquisition to boost its pipeline with next-gen cell therapy tech. The deal includes Capstan's lead drug, CPTX2309, a Phase 1 in vivo CAR-T therapy aimed at treating autoimmune diseases by reprogramming immune cells inside the body using mRNA and lipid nanoparticles. Overall, AbbVie's efforts to expand its drug pipeline are impressive and bode well for long-term growth. Is ABBV a Buy, Hold, or Sell? Turning to Wall Street, ABBV stock has a Moderate Buy consensus rating based on 11 Buys and six Holds assigned in the last three months. At $213, the average AbbVie price target implies a 12.53% upside potential. The stock has gained 5.1% over the past six months.
Yahoo
01-07-2025
- Business
- Yahoo
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Capstan Therapeutics, for up to $2.1 billion in cash. The impending acquisition will add Capstan's lead asset, CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy, to AbbiVie's immunology pipeline. The acquisition will also add Capstan's proprietary tLNP platform technology, CellSeeker, which helps deliver RNA, like mRNA, to engineer specific cell types inside the body. CPTX2309 is an in vivo CAR-T therapy using tLNPs to reprogram T cells, aiming to treat autoimmune diseases. The candidate is currently in phase I development for treating B-cell-mediated autoimmune diseases. The acquisition is subject to customary closing conditions, including regulatory approvals. Year to date, shares of AbbVie have risen 4.5% against the industry's decline of 2.6%. Image Source: Zacks Investment Research AbbVie has been on an acquisition spree lately, which is strengthening its pipeline. Particularly, it is signing several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience areas. It has signed more than 20 early-stage deals since the beginning of 2024, including promising technologies and innovative mechanisms that can elevate the standard of care in immunology, oncology and neuroscience. Earlier this year, AbbVie bought rights to develop GUB014295 (ABBV-295), a long-acting amylin analog for the treatment of obesity, from Denmark's Gubra. The deal marked AbbVie's entry into the lucrative obesity space. In January 2025, AbbVie completed the acquisition of Nimble Therapeutics. The acquisition added Nimble's lead asset, an investigational oral peptide IL23R inhibitor currently in preclinical development for the treatment of psoriasis. The acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics for autoimmune diseases. AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Exelixis EXEL, Spero Therapeutics SPRO and Puma Biotechnology PBYI, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for Exelixis' earnings per share have increased from $2.31 to $2.64 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.85 to $3.13. Year to date, shares of EXEL have rallied 32.4%. EXEL's earnings beat estimates in each of the trailing four quarters, the average surprise being 48.60%. In the past 60 days, estimates for Spero Therapeutics' loss per share have narrowed from $2.32 to $1.43 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.98 to $1.15. Year to date, shares of SPRO have surged 181.5%. SPRO's earnings beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions, the average surprise being 8.29%. In the past 60 days, estimates for Puma Biotechnology's earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have risen from 46 cents to 51 cents. Year to date, shares of PBYI have gained 12.5%. PBYI's earnings beat estimates in each of the trailing four quarters, the average surprise being 171.43%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report Spero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
01-07-2025
- Business
- Business Insider
AbbVie Stock (ABBV) Jumps on $2.1B Capstan Therapeutics Deal
AbbVie (ABBV) stock rallied on Monday after the company announced its $2.1 billion agreement to acquire Capstan Therapeutics. It will use cash to fund this transaction, which still needs to complete customary closing conditions before it's finalized. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. AbbVie's interest in Capstan Therapeutics has to do with CPTX2309. This is a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate undergoing a Phase 1 clinical trial. It's designed to treat B cell-mediated autoimmune diseases, which occur when the body's own immune system attacks it. This would reset the immune system, curing the disease instead of just treating its symptoms. Laura Shawver, Ph.D., President and CEO of Capstan Therapeutics, said, 'Through AbbVie's world-leading expertise in immunology research, clinical development, and its commercialization capabilities, we believe that this transaction moves us closer to delivering on our shared mission to bring these innovative therapies to patients in need.' AbbVie Stock Movement Today ABBV stock was up 1.5% as of this writing, suggesting investors were pleased with its planned purchase of Capstan Therapeutics. This also extended its 6.08% year-to-date rally and 7.01% rise over the past 12 months. Today's news saw some 1 million shares traded, which is still below the company's three-month daily average trading volume of about 5.89 million units. Is AbbVie Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for AbbVie is Moderate Buy, based on 11 Buy and six Hold ratings over the past three months. With that comes an average ABBV stock price target of $212.80, representing a potential 14.86% upside for the shares. Spark, TipRanks' AI analyst, cites 'strong financial performance, particularly in cash flow generation and operational profitability, coupled with positive earnings call highlights' as the reasons behind its Buy rating for ABBV stock.
CNBC
30-06-2025
- Business
- CNBC
AbbVie to buy Capstan Therapeutics for up to $2.1 billion
AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion. Capstan develops CAR-T therapies, a type of treatment that uses a patient's own immune cells, specifically T cells, to fight diseases. Its main drug, CPTX2309, is currently in development for the treatment of autoimmune diseases. AbbVie has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection last year.
